Blocking peanut allergy through protective IgG antibodies
Ended · France
Source: EU Funding & Tenders Portal
Food allergies are chronic diseases of increasing prevalence for which there is no approved treatment other than food allergen avoidance. Among all food allergies, peanut allergy is a particularly important public health problem since peanut allergy tends to persist throughout life and is more likely than other types of food allergies to cause severe shock (i.e., “anaphylaxis”) and death. The curr
- Status
- Closed
- Sector
- Government
- Location
- France
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Blocking peanut allergy through protective IgG antibodies
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Food allergies are chronic diseases of increasing prevalence for which there is no approved treatment other than food allergen avoidance. Among all food allergies, peanut allergy is a particularly important public health problem since peanut allergy tends to persist throughout life and is more likely than other types of food allergies to cause severe shock (i.e., “anaphylaxis”) and death. The current paradigm states that peanut allergy is mostly triggered by IgE antibodies. Evidence derived from mouse models indicates that some IgG isotypes can also mediate allergic reactions, but the roles of human IgG in peanut allergy remain unknown. Among the potential treatments for peanut allergy under investigation, oral immunotherapy (OIT) appears very promising since subjects completing OIT tolerate food challenges despite persistent high-titers of IgE in the blood. OIT consists of the administration of slowly increasing doses of the allergenic food and is associated with the production of large levels of IgG, but a direct link between these antibodies and the beneficial effects of OIT has not been demonstrated. We hypothesize that peanut allergic patients produce both pro-allergic and protective IgG, and that successful OIT is associated with an increased production of protective IgG that are particularly potent at blocking the allergic reaction. We propose to test this hypothesis by developing and exploiting humanized mouse models of peanut allergy, combined with the use of clinical samples and purified IgG from peanut allergic patients completing a phase 2 OIT clinical trial. Finally, we aim at establishing the proof of concept that recombinant protective human IgG could be used to treat peanut allergy and improve the safety and efficiency of current OIT protocols. |
Location
Country | France |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2026-01-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Government projects in France
- Projet 18e - Porte de Clignancourt
- Projet Broussais
- 250 premiers projets pour entretenir et rénover Paris
- Protocole d'accord RATP/Ville de Paris: création de 2000 logements d'ici 2024
- Chapelle Dubois Condorcet
- Les dix lauréats de l'appel à projets de l'Arc de l'innovation
- Projet 16e - 17e - Porte Maillot
- Sanofi Pasteur Vaccine Plant, Val De Reuil, France
